Unsupervised 12-week PACE exercise prescription in overweight or obese geriatric outpatients
In a single-arm study, 37 overweight or obese geriatric outpatients completed a 12-week unsupervised PACE exercise prescription; lower-limb muscle function and endurance improved and probable sarcopenia prevalence fell, but there was no control group. [1]
Automatic summary · not editorially reviewed
The key findings
Thirty-seven overweight or obese geriatric outpatients aged 60 or older completed a 12-week unsupervised home-based PACE prescription combining individualized functional and resistance exercises with walking. [1]
Participants averaged 238 ± 140 minutes of physical activity per week, and 65% met recommended activity guidelines. [1]
The prevalence of probable sarcopenia decreased significantly (p = 0.011), and clinically meaningful improvements were reported in muscle endurance. [1]
The source at a glance
- Study type / format
- Single-arm interventional study (abstract)
- Population / context
- Geriatric outpatients aged 60 or older with overweight or obesity; 37 participants, 20 women.
- Summary based on
- Study abstract
- Publication status
- Preprint · peer-review status not confirmed
- Original publication
- September 10, 2026
PACE tested in 37 geriatric outpatients
The abstract describes a single-arm interventional study of geriatric outpatients aged 60 or older who were overweight or obese. Thirty-seven participants, 20 of them women, completed the 12-week home-based PACE prescription. It combined individualized functional and resistance exercises with walking and was unsupervised. The authors note that physical activity is protective in this group but that prescription and adherence are low, so they tested a pragmatic, scalable program.
Supporting source [1]
Muscle function and probable sarcopenia changes
Participants averaged 238 ± 140 minutes of physical activity per week, and 65% met recommended activity guidelines. The abstract reports significant improvements in lower-limb muscle function (p = 0.033) and endurance (p = 0.006) and in absolute (p = 0.038) or relative (p = 0.045) estimated muscle power. The prevalence of probable sarcopenia decreased significantly (p = 0.011), and clinically meaningful improvements were reported in muscle endurance. These are within-group changes in a single-arm design, so they do not by themselves show that PACE caused the improvements.
Supporting source [1]
Abstract-only scope and missing control group
The available text is an abstract; the full text was not reviewed. It reports a single-arm design without a control group, so improvements cannot be separated from other influences. The abstract does not report follow-up beyond the 12 weeks or how adherence was measured. The authors suggest PACE could be a pragmatic, scalable strategy and might support healthy aging and help prevent sarcopenia-obesity related functional decline; these are proposals, not demonstrated long-term outcomes.
Supporting source [1]
How to interpret this
Abstract only; the full text was not reviewed. Single-arm design without a control group, so changes cannot be attributed to PACE. No follow-up beyond 12 weeks and no detail on how adherence was measured are reported.
Based on the study abstract; the full paper, tables and supplementary data were not reviewed.
Source & supporting passages
El-Oueslati H, Youssef L, F-J-M R, Boucher L, Tannou T, Brodeur C, Andriamampionona F, M-J K, Aubertin-Leheudre M. · europepmc.org · September 10, 2026